Federal hair-relaxer claims remain in active coordinated pretrial proceedings in MDL 3060 in the Northern District of Illinois. The Judicial Panel on Multidistrict Litigation (JPML) reported 12,129 pending actions as of September 1, 2026. The official records reviewed through September 7, 2026 do not establish a global settlement, fixed payout schedule, settlement fund, or completed bellwether verdict. The lawsuits allege that chemical hair-relaxer use contributed to specified cancers and other injuries; defendants dispute liability, and no single study or MDL filing proves individual causation.

Hair Relaxer Lawsuit Status: 2026 Update

As of September 7, 2026, the litigation involving chemical hair relaxers remains active in federal court. While thousands of individual plaintiffs have filed claims, it is important to distinguish active litigation from a final resolution.

The current volume of cases does not serve as a measure of the merits of the claims; rather, it reflects the number of individuals who have sought legal recourse. Defendants, including major cosmetic manufacturers, continue to contest the allegations, and the court has not yet ruled on the ultimate question of whether these products cause the injuries alleged in the complaints.

What MDL 3060 Means—and What It Does Not Mean

The hair relaxer litigation is centralized in multidistrict litigation (MDL). The JPML's February 6, 2023 Transfer Order assigned the federal actions to Judge Mary M. Rowland in the Northern District of Illinois for coordinated or consolidated pretrial proceedings. This is a procedural tool for managing cases that share common factual questions.

• It is not a Class Action: Unlike a class action, where one representative case decides the outcome for all members, an MDL preserves the individuality of each lawsuit. Each plaintiff must eventually prove their own specific exposure and injury.
• Coordinated Discovery: The MDL allows for a single discovery process regarding the manufacturers' conduct and the general science of the chemicals involved. This prevents 12,000 different judges from making conflicting procedural rulings.
• No Guarantee of Recovery: The existence of an MDL does not mean the defendants have been found liable. It is a pretrial phase designed for efficiency.

[hair_long_1]

Where the Bellwether Process Stands

To manage the vast number of claims, the court uses a "bellwether" process. This involves selecting a small group of representative cases to go through full discovery and trial. The results of these trials are not binding on other plaintiffs, but they provide "signals" to both sides about how juries might react to the evidence, which often facilitates settlement discussions.

Key Procedural Milestones

The court has issued several Court Management Orders (CMOs) that define the current landscape:

• Injury Designation (CMO 15): The initial bellwether selection process focuses on claims involving uterine cancer, endometrial cancer, and ovarian cancer.
• Science Day (CMO 21): The court scheduled a January 8, 2026 "Science Day." By the order's terms, the planned presentations were educational and non-evidentiary, not a forum for final rulings on expert testimony. The order alone does not prove the proceeding occurred or that the court accepted either side's position.
• Second-Wave Discovery (CMO 24): Discovery for the defendants named in that order is active, with written discovery scheduled through March 1, 2027, and oral fact discovery through July 15, 2027. Those are discovery deadlines, not claim-filing or trial dates.

What Plaintiffs Allege and What the Science Shows

The complaints allege that certain hair-relaxer products contained phthalates or other endocrine-disrupting chemicals and that exposure contributed to reproductive-system injuries. The JPML described chemical causation as a disputed common question for coordinated litigation, not as an established fact.

The NIH Sister Study

Much of the recent legal activity followed the 2022 publication of an NIH-led observational study. The NIH release and peer-reviewed study abstract support several carefully limited points:

• Association, Not Causation: The study found an observational association between frequent hair straightener use and uterine cancer. It did not prove that the products caused the cancer.
• Frequent Use Defined: The increased risk was most notable in women who reported using the products more than four times in the previous year.
• Data Limitations: The study did not collect data on specific brands or specific chemical ingredients in the products used by participants.

Defendants argue that the science is insufficient to establish a direct link between their specific products and the injuries reported by plaintiffs.

[hair_long_2]

Claim-Strength Documentation Checklist

Attorneys evaluating a potential claim look for evidence connecting product use, timing, diagnosis, and damages. While the following list does not guarantee eligibility, it reflects categories addressed in the MDL's Plaintiff Fact Sheet process and additional records that may help counsel investigate an individual claim:

• Product Identification: Exact names of products used and the names of the manufacturers.
• Exposure History: Approximate dates of first and last use, and the frequency of application (e.g., every 6 weeks).
• Purchase Proof: Receipts, loyalty program records, or photographs of containers if available.
• Service Records: Salon names, locations, and stylist testimony if the products were applied professionally.
• Medical Diagnosis: Official pathology reports and diagnosis records for uterine, endometrial, or ovarian cancer.
• Treatment History: Records of surgeries (such as hysterectomies), chemotherapy, or radiation.
• Medical Background: Records identifying potential alternative causes or genetic predispositions.
• Economic Impact: Documentation of lost income or employment changes due to the illness.

[hair_long_3]

How Lawyers Evaluate an Individual Claim

When a law firm reviews a hair relaxer case, they perform a multi-factor analysis to determine if the claim is viable for filing:

1. Product Identification: Can the person identify a specific product and manufacturer with enough detail for counsel to investigate the responsible parties?
2. Exposure Duration: Was the product used consistently over a period of years?
3. Latency and Timing: Did the injury occur after a sufficient period of exposure, or did the diagnosis happen before the product was used?
4. Statute of Limitations: Does the claim comply with the filing deadlines of the plaintiff’s home state?
5. Causation Hurdles: Are there other significant risk factors in the plaintiff’s medical history that a defense expert might argue caused the injury?

Settlement and Compensation Reality

There is currently no hair relaxer settlement fund. Any figures cited online regarding "average payouts" or "settlement tiers" are speculative. In complex litigation, if a settlement is eventually reached, compensation is usually determined by a "matrix" that considers:

• The severity of the injury.
• The age of the plaintiff at the time of diagnosis.
• The duration of product use.
• The extent of medical expenses and lost wages.

While bellwether trials help parties value claims, they do not automatically set the amount for every individual in the MDL.

[hair_compensation_short_1]

Deadlines and State-Law Caution

The timeframe to file a lawsuit, known as the statute of limitations, is not universal. It varies significantly by state and by the facts. Some jurisdictions apply discovery rules that may affect when a claim accrues based on when a person knew or reasonably should have known relevant facts; some also have statutes of repose that can impose a separate outside limit. The governing law and trigger date require an individualized analysis.

Relying on general statements such as "diagnosed within the last few years" is risky. Legal rights are best preserved by seeking a specific evaluation of the laws in your jurisdiction as they apply to your diagnosis date.

[hair_statute_short_1]

Practical Steps While the MDL Is Active

Someone considering a case can improve the quality of a legal evaluation without assuming that a claim is valid. First, write a product-use history while memories are fresh, separating what is known from what is estimated. Record product names, package colors, manufacturers, salons, approximate dates, and application frequency. Preserve containers, labels, photographs, receipts, loyalty-account histories, and messages with stylists when available; do not create or alter evidence.

Second, collect medical records that establish the diagnosis and treatment history, especially pathology reports, operative reports, and records identifying the date of diagnosis. A complete history is more useful than a hand-picked set because counsel and experts must consider alternative risk factors as well as the claimed exposure.

Third, identify prior claims, bankruptcies, settlements, or lawsuits that might affect disclosure obligations. The federal MDL's Short Form Complaint and Plaintiff Fact Sheet are formal litigation documents, and inaccurate or incomplete responses can create serious problems. Prospective claimants should not copy another person's answers or rely on a marketing site's checklist as legal advice.

Finally, ask any reviewing lawyer to explain which jurisdiction's deadline may apply, which product and injury evidence is still missing, whether the contemplated case would be filed in or transferred to MDL 3060, and what costs or obligations the representation agreement assigns. These steps support a better evaluation; they do not promise acceptance, filing, settlement, or recovery.

Litigation Timeline

The following events represent the official procedural history of MDL 3060:

• 2026-09-01 — JPML reports 12,129 pending actions. This update includes a total of 16,561 historical actions filed since the inception of the MDL; however, pending counts do not reflect the ultimate success of the claims.
• 2026-08-27 — Second-wave discovery schedule entered. Under CMO 24, the court established that written discovery will continue through March 1, 2027, with oral fact discovery for second-wave defendants extending to July 15, 2027.
• 2025-06-25 — Science Day procedures entered. CMO 21 scheduled an educational, non-evidentiary proceeding for January 8, 2026, to familiarize the court with the scientific principles of the case.
• 2025-03-05 — Bellwether selection process established. CMO 15 outlined the framework for selecting representative cases, focusing on uterine, endometrial, and ovarian cancer allegations.
• 2024-03-15 — Dismissal/refiling procedure entered. CMO 10 provided protocols for managing case filings and dismissals, without guaranteeing that any individual can refile a claim today.
• 2023-12-19 — Plaintiff Fact Sheet process established. CMO 9 mandated the submission of detailed claimant data; these internal litigation deadlines are separate from state statutes of limitation.
• 2023-08-03 — Short Form Complaint adopted. CMO 7 approved a standardized Short Form Complaint process for covered member actions; filing the form does not prove a claim.
• 2023-02-06 — Federal cases centralized in MDL 3060. The JPML transferred the actions listed in its order to the Northern District of Illinois for coordinated or consolidated pretrial proceedings.

[hair_justice_short_1]

Frequently Asked Questions

Is there a hair relaxer settlement? The official records reviewed through September 7, 2026 do not establish a global settlement or court-ordered compensation fund. The federal litigation remains in active pretrial proceedings.

Is the MDL a class action? No. MDL 3060 is a coordination of individual lawsuits. While they share discovery, each plaintiff must prove their own case to receive compensation.

Which diagnoses are in the initial bellwether process? The court has prioritized uterine cancer, endometrial cancer, and ovarian cancer for the initial pool of bellwether cases.

What records should someone preserve? Individuals should keep all medical records, pathology reports, receipts for hair products, and contact information for hair salons where relaxers were applied.

Does the NIH study prove a claim? No. The NIH study reports a statistical association, but it does not identify a specific brand or ingredient and does not establish that a product caused a particular person's diagnosis. Product identification, individual medical evidence, applicable law, and admissible causation evidence may all matter in a litigated claim.

Legal.com Liability Disclaimer

All content published by Legal.com is provided for general informational purposes only. It is not legal advice, does not constitute a legal opinion, and should not be relied upon as a substitute for consultation with a qualified attorney. No attorney-client relationship is created by reading this article, using Legal.com templates, or contacting Legal.com. Legal.com disclaims all liability for actions taken or not taken based on this publication.